Table 2.
NCSLC patients EGFR mutation rate and clinical information analysis by NGS
| Overall patients | Case(n) | EGFR | Positive rate (%) | χ2 (Bray et al. 2018) | P | |
|---|---|---|---|---|---|---|
| Mutated type | Wild type | |||||
| Sex | ||||||
| Male | 468 | 141 | 327 | 30.1 | 69.23 | 0.00 |
| Female | 334 | 199 | 135 | 59.6 | ||
| Age | ||||||
| < 45 | 32 | 12 | 20 | 37.5 | 12.087 | 0.13 |
| 45 ~ 59 | 256 | 123 | 133 | 48.0 | ||
| 60 ~ 74 | 379 | 163 | 216 | 43.0 | ||
| 75 ~ 89 | 131 | 42 | 89 | 32.1 | ||
| > 90 | 4 | 0 | 4 | 0.0 | ||
| Sample type | ||||||
| Tumor tissue | 442 | 206 | 236 | 46.6 | 24.109 | 0.00 |
| Metastatic tissue | 3 | 1 | 2 | 33.3 | ||
| Cytology | 49 | 31 | 18 | 63.3 | ||
| Sputum | 8 | 4 | 4 | 50.0 | ||
| Blood | 300 | 98 | 202 | 32.7 | ||